



28 July 2021

## Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> of August 2021 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

Pharmac cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

## 2020/21 Tender – Principal Supply Status applies until 30 June 2024

### CORRECTION to June 2021 tender notification

Pharmac incorrectly notified a Principal Supply Status award in the Community and Hospital in June 2021 for mometasone furoate. Correction in strikethrough and bold below:

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

### Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Mometasone furoate	Crn 0.1%; 15 g OP tube	\$1.51	\$1.95	Elocon Alcohol Free ( <del>MSD</del> Organon (New Zealand) Limited)	1 September 2021	1 February 2022
Mometasone furoate	Crn 0.1%; 50 g OP tube	\$2.50	\$3.10	Elocon Alcohol Free ( <del>MSD</del> Organon (New Zealand) Limited)	1 September 2021	1 February 2022
Mometasone furoate <sup>1</sup>	Lotn 0.1%; 30 ml OP bottle	\$6.30	\$4.50	Elocon ( <del>MSD</del> Organon (New Zealand) Limited)	1 September 2021	1 February 2022
Mometasone furoate	Oint 0.1%; 15 g OP tube	\$1.51	\$1.95	Elocon ( <del>MSD</del> Organon (New Zealand) Limited)	1 September 2021	1 February 2022
Mometasone furoate <sup>1</sup>	Oint 0.1%; 50 g OP tube	\$2.90	\$2.90	Elocon ( <del>MSD</del> Organon (New Zealand) Limited)	1 September 2021	1 February 2022

<sup>1</sup>This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender.

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

### Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date
Mometasone furoate	Crm 0.1%; 15 g OP tube	\$1.51	\$1.95	Elocon Alcohol Free (MSD Organon (New Zealand) Limited)	5%	1 September 2021	1 February 2022
Mometasone furoate	Crm 0.1%; 50 g OP tube	\$2.50	\$3.10	Elocon Alcohol Free (MSD Organon (New Zealand) Limited)	5%	1 September 2021	1 February 2022
Mometasone furoate <sup>2</sup>	Lotn 0.1%; 30 ml OP bottle	\$6.30	\$4.50	Elocon (MSD Organon (New Zealand) Limited)	5%	1 September 2021	1 February 2022
Mometasone furoate	Oint 0.1%; 15 g OP tube	\$1.51	\$1.95	Elocon (MSD Organon (New Zealand) Limited)	5%	1 September 2021	1 February 2022
Mometasone furoate <sup>2</sup>	Oint 0.1%; 50 g OP tube	\$2.90	\$2.90	Elocon (MSD Organon (New Zealand) Limited)	5%	1 September 2021	1 February 2022

<sup>2</sup>This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender.

## 2020/21 Tender – Principal Supply Status applies until 30 June 2024

### Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

See table 4 below for changes to Section B of the Pharmaceutical Schedule in relation to fluorouracil.

## 2020/21 Tender – Principal Supply Status applies until 30 June 2024

### Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply date
Flumazenil	Inj 0.1 mg per ml, 5 ml ampoule; 10 ampoule pack	\$132.68	\$110.12	HamelN (Max Health)	5%	1 September 2021	1 February 2022

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Fluorouracil <sup>1</sup>	Inj 50 mg per ml, 20 ml vial; 1 vial pack	\$12.00	\$10.51	Fluorouracil Accord (Accord)	5%	1 September 2021	1 February 2022	Fluorouracil Ebewe (Sandoz)
Fluorouracil <sup>1</sup>	Inj 50 mg per ml, 100 ml vial; 1 vial pack	\$30.00	\$29.44	Fluorouracil Accord (Accord)	5%	1 September 2021	1 February 2022	Fluorouracil Ebewe (Sandoz)

<sup>1</sup>The price and subsidy of Fluorouracil (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 September 2021. The subsidy of fluorouracil (Baxter) inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will also be amended from \$0.66 per 1 mg to \$0.62 per 1 mg from 1 September 2021.

For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.